Similarly, in other tumor types, such as melanoma, breast cancer, and colon cancer, (national) guidelines include indications for the use of targeted therapies in patients with specific molecular aberrations, such as BRAF V600 mutations in melanoma and colon cancer, and PIK3CA mutations in breast cancer.10 This evidence concerns the gene BRAF and breast carcinoma.